Home

Laurence Reid

CIK 1492749 · See Remarks · last filed 2026-06-11

Laurence Reid is a corporate insider who has filed 26 SEC Form 4 insider transactions across 4 companies since 2010. The most recent filing, for MGX, was dated Jun 11, 2026. Across all open-market trades the lifetime net is −$4.4M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $5.6M across reported positions. 21 SEC filings were submitted jointly with ALNYLAM PHARMACEUTICALS, INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$5.64M

Companies

4

Total Filings

26

Lifetime Open-Market Net

-$4.36M

Filer Profile

Reported Address
300 THIRD STREET
55 CAMBRIDGE PARKWAY, SUITE 901E
CAMBRIDGE, MA 02142
Related Filers
ALNYLAM PHARMACEUTICALS, INC. — 21 joint filings, latest 2015-01-05
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
MGX Director — $1.16 — $0 2 2026-06-11
KalVista Pharmaceuticals, Inc. (KALV) Delisted Director — $27.00 — $0 2 2026-06-11
Decibel Therapeutics, Inc. (DBTX) Delisted See Remarks 0 $4.91 $0 $76.4K 4 2023-09-25
ALNY SVP, Chief Business Officer 22,671 $248.68 $5.64M -$4.43M 18 2015-01-05

Recent Filings

26 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-11 MGX Grant (A) — $0 EDGAR
2026-06-11 KalVista Pharmaceuticals, Inc. (KALV) Delisted Disp (D) — $0 EDGAR
2025-09-02 MGX Grant (A) — $0 EDGAR
2024-11-26 KalVista Pharmaceuticals, Inc. (KALV) Delisted Grant (A) — $0 EDGAR
2023-09-25 Decibel Therapeutics, Inc. (DBTX) Delisted Disp (D) −220,849 $0 EDGAR
2023-03-17 Decibel Therapeutics, Inc. (DBTX) Delisted Grant (A) +195,000 $0 EDGAR
2022-02-28 Decibel Therapeutics, Inc. (DBTX) Delisted Grant (A) — $0 EDGAR
2021-09-17 Decibel Therapeutics, Inc. (DBTX) Delisted Buy (P) +10,000 $76.4K EDGAR
2015-01-05 ALNY Mixed +14,198 $36 EDGAR
2014-12-16 ALNY Grant (A) — $0 EDGAR
Showing 1–10 of 26
Page 1 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.